These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 24676887)

  • 1. Low-energy femoral shaft fractures after long-term alendronate therapy: report of seven cases.
    Ballas EG; Mavrogenis AF; Karamanis E; Kokkalis ZT; Mitsiokapa E; Koulalis D; Mastrokalos D; Papagelopoulos PJ
    Eur J Orthop Surg Traumatol; 2015 Jan; 25(1):181-7. PubMed ID: 24676887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-energy femoral shaft fractures associated with alendronate use.
    Neviaser AS; Lane JM; Lenart BA; Edobor-Osula F; Lorich DG
    J Orthop Trauma; 2008; 22(5):346-50. PubMed ID: 18448990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Case reports: subtrochanteric femoral stress fractures after prolonged alendronate therapy.
    Cermak K; Shumelinsky F; Alexiou J; Gebhart MJ
    Clin Orthop Relat Res; 2010 Jul; 468(7):1991-6. PubMed ID: 20020334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy?
    Kwek EB; Goh SK; Koh JS; Png MA; Howe TS
    Injury; 2008 Feb; 39(2):224-31. PubMed ID: 18222447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bisphosphonates and low-impact femoral fractures: current evidence on alendronate-fracture risk.
    Schneider JP
    Geriatrics; 2009 Jan; 64(1):18-23. PubMed ID: 19256578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-energy femoral fractures associated with the long-term use of bisphosphonates: a case series from a Swiss university hospital.
    Ing-Lorenzini K; Desmeules J; Plachta O; Suva D; Dayer P; Peter R
    Drug Saf; 2009; 32(9):775-85. PubMed ID: 19670917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bilateral atypical femoral diaphyseal fractures in a patient treated with alendronate sodium.
    Lee JK
    Int J Rheum Dis; 2009 Jul; 12(2):149-54. PubMed ID: 20374333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subtrochanteric femoral fractures in patients receiving long-term alendronate therapy: imaging features.
    Chan SS; Rosenberg ZS; Chan K; Capeci C
    AJR Am J Roentgenol; 2010 Jun; 194(6):1581-6. PubMed ID: 20489100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Femoral shaft fractures in the elderly--role of prior bisphosphonate therapy.
    Ng YH; Gino PD; Lingaraj K; Das De S
    Injury; 2011 Jul; 42(7):702-6. PubMed ID: 21316051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Case reports: two femoral insufficiency fractures after long-term alendronate therapy.
    Sayed-Noor AS; Sjödén GO
    Clin Orthop Relat Res; 2009 Jul; 467(7):1921-6. PubMed ID: 19198962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bilateral low-energy sequential femoral shaft fractures in patients on long-term bisphosphonate therapy.
    Çakmak S; Mahiroğulları M; Keklikçi K; Sarı E; Erdik B; Rodop O
    Acta Orthop Traumatol Turc; 2013; 47(3):162-72. PubMed ID: 23748615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bilateral low-energy simultaneous or sequential femoral fractures in patients on long-term alendronate therapy.
    Capeci CM; Tejwani NC
    J Bone Joint Surg Am; 2009 Nov; 91(11):2556-61. PubMed ID: 19884427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of long-term alendronate treatment on cortical thickness of the proximal femur.
    Unnanuntana A; Ashfaq K; Ton QV; Kleimeyer JP; Lane JM
    Clin Orthop Relat Res; 2012 Jan; 470(1):291-8. PubMed ID: 21773861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-energy diaphyseal femoral fractures associated with bisphosphonate use and severe curved femur: a case series.
    Sasaki S; Miyakoshi N; Hongo M; Kasukawa Y; Shimada Y
    J Bone Miner Metab; 2012 Sep; 30(5):561-7. PubMed ID: 22610061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bisphosphonate-related subtrochanteric femoral fractures.
    Gunawardena I; Baxter M; Rasekh Y
    Am J Geriatr Pharmacother; 2011 Jun; 9(3):194-8. PubMed ID: 21470918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bilateral atypical femoral fractures after long-term alendronate therapy: a case report.
    Bamrungsong T; Pongchaiyakul C
    J Med Assoc Thai; 2010 May; 93(5):620-4. PubMed ID: 20524451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequential subtrochanteric femoral fracture after atypical diaphyseal fracture in a long-term bisphosphonate user: a case report.
    Park KT; Lee KB
    Acta Chir Orthop Traumatol Cech; 2015; 82(2):157-60. PubMed ID: 26317188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Localized cortical thickening of the femoral diaphysis captured on an X-ray before alendronate therapy in two cases of atypical femoral fracture.
    Iizuka Y; Takechi R; Iizuka H; Omodaka T; Takagishi K
    Skeletal Radiol; 2016 Oct; 45(10):1403-7. PubMed ID: 27402027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are women with thicker cortices in the femoral shaft at higher risk of subtrochanteric/diaphyseal fractures? The study of osteoporotic fractures.
    Napoli N; Jin J; Peters K; Wustrack R; Burch S; Chau A; Cauley J; Ensrud K; Kelly M; Black DM
    J Clin Endocrinol Metab; 2012 Jul; 97(7):2414-22. PubMed ID: 22547423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-traumatic fracture of the femoral shaft in a patient taking long-term bisphosphonate therapy.
    Ahn JK; Lee J; Cha HS; Koh EM
    Rheumatol Int; 2011 Jul; 31(7):973-5. PubMed ID: 20383511
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.